TTR and heart failure: Clinical trials have demonstrated that Tafamidis significantly reduces mortality and cardiovascular-related hospitalizations compared to placebo.19 Other agents include transthyretin reduction therapies such as patisiran or inotersen, alongside symptomatic treatments for heart failure, such as diuretics.